Halozyme Therapeutics Boosts Revenue Guidance, Analysts React
Halozyme Therapeutics' Earnings Performance Insights Recently, analysts adjusted their outlook for Halozyme Therapeutics (NASDAQ: HALO), following a robust earnings report for the third quarter of 2024. Piper Sandler increased its price target to $52 from $51, while maintaining a Neutral rating on the stock. This adjustment came in light of Halozyme's impressive...
Continue Reading